In a small, randomized, within-subjects, placebo-controlled study designed to investigate whether a single dose of OXT could improve higher-order and lower-order social cognition, patients with schizophrenia received a single dose of oxytocin nasal spray (24 IU) and a placebo, administered 2 weeks apart [126]. This evidence concerns the gene OXT and schizophrenia.